Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
Disease Category: Prostate Cancer
Location: United States, ND
Clinical Trial Details
Research Study Summary
A research study for patients who have been diagnosed with metastatic, castrate-resistant prostate cancer
A study to evaluate a new way of potentially treating prostate cancer using a new vaccine that may help cells from your own body to recognize and kill the cancer cells.
Patient Inclusion Criteria:
- Men 18 – 85 years of age with documented asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer
- Life expectancy >1 year
- Chemotherapy naïve
- No significant cardiovascular disease
- No contraindication for vaccinia immunization
Patient Exclusion Criteria:
- Chemotherapy: Concomitant use of chemotherapy is not allowed during the Treatment phase (approximately 5 months) of this trial.
- Anti-cancer radionuclides: Concomitant use of anti-cancer radionuclides is not allowed during the Treatment phase of this trial.
- Secondary hormonal therapies: Concomitant use of supplementary hormonal treatments is not allowed during the Treatment phase of this trial.
- Corticosteroids: Concomitant chronic use of systemic corticosteroids is not allowed during the Treatment phase of the study. The use of inhaled corticosteroids, nasal sprays, and topical creams for small body areas is allowed.
To Learn more
Date Last Changed:
July 18, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.